Extracellular vesicle miR-425-5p promotes visceral fat reduction via DACT1 suppression in SGLT2i-treated diabetes.

Front Endocrinol (Lausanne) · 2025 · PMC12723516 · PMID 41446634

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

near-significantno p-value reported

Furthermore, our data showed that several clinical parameters, including fasting glucose, HbA1c, and systolic blood pressure, showed significant or near-significant improvements after 6 months of SGLT2i treatment, whereas the expression of plasma-derived EV miRNAs, including miR-425-5p, remained unchanged for up to 12 months.

also in 2,306 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.